

wherein:

n is an integer from 2-8;

X_1 is a cholic acid group or deoxycholic acid group; and X_2 and X_3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups;

and wherein at least one of X_2 and X_3 is a saccharide group.

22. (Amended) A pharmaceutical composition comprising a mucoadhisive and a therapeutically effective amount of a therapeutic agent formulated in a buffer comprising a compound of Formula I:



wherein:

n is an integer from 2-8;

X_1 is a cholic acid group or deoxycholic acid group; and X_2 and X_3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups;

and wherein at least one of X_2 and X_3 is a saccharide group.

35. (Amended) A method of treating bladder cancer comprising administration to a cell of a therapeutically effective amount of a therapeutic gene that is formulated in a buffer, wherein the therapeutically effective amount of a therapeutic gene is in the range of about from $1x10^8$ particles/ml to $5x10^{11}$-particles/ml of a recombinant adenovirus in which the therapeutic gene is inserted, comprising a compound of Formula I:



wherein:

n is an integer from 2-8;

X_1 is a cholic acid group or deoxycholic acid group; and X_2 and X_3 are each independently selected from the group consisting of a cholic acid group, a deoxycholic acid group, and a saccharide group, wherein the saccharide group is selected from the group consisting of pentose monosaccharide groups, hexose monosaccharide groups, pentose-pentose disaccharide groups, hexose-hexose disaccharide groups, pentose-hexose disaccharide groups, and hexose-pentose disaccharide groups;

and wherein at least one of X_2 and X_3 is a saccharide group.

36. (Amended) A method of treating bladder cancer comprising administration to a cell of a therapeutically effective amount of a therapeutic gene that is formulated in a buffer, wherein the therapeutically effective amount of a therapeutic gene is in the range of about from $1x10^9$ particles/ml to $5x10^{11}$-particles/ml of a recombinant adenovirus in which the therapeutic gene is inserted, comprising a compound of Formula I:



wherein:

n is an integer from 2-8;